Forensic Analysis · Professional & Commercial Services · as of Aug 11, 2026

Neogenomics Inc (NEO)

A forensic read on Neogenomics Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Safe

Financial health

4.0

Distress distance

Clean

Earnings quality

Forensic signals

-8.4

P / E (ttm)

-12.9%

ROE

$2.1B

Market cap

0.00%

Dividend yield

10.1%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Neogenomics Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 4.0, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.

What the filings flag

-8.2%

FY2025

Return on invested capital. Return on invested capital is -8.2% in the latest fiscal year and steady — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

+1.0%/yr

FY2022–FY2025

Share-count dilution. Diluted share count changed +3% over the last 3 years to FY2025 (+1.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~1.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~3%.

$4M

FY2025–FY2025

Goodwill impairments. Took $4M of goodwill writedowns across 1 year (FY2025 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$727.3M

Revenue Growth YoY+10.1%

Revenue CAGR (3yr)+12.6%

Net Margin-14.9%

Free Cash Flow-$21.8M

Return on Equity-12.9%

Debt / Equity0.41x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Neogenomics Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.